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Members of the Oxa1p/Alb3/YidC family mediate the
insertion of various organelle or bacterial hydrophobic
proteins into membranes. They present at least five
transmembrane segments (TM) linked by hydrophilic
domains located on both sides of the membrane. To ex-
amine how Oxa1p structure relates to its function, we
have introduced point mutations and large deletions
into various domains of the yeast mitochondrial protein.
These mutants allowed us to show the importance of the
first TM domain as well as a synergistic interaction be-
tween the first loop and the C-terminal tail, which both
protrude into the matrix. These mutants also led to the
isolation of a high copy suppressor, OMS1, which en-
codes a member of the methyltransferase family. Over-
expression of OMS1 seems to increase the steady-state
level of both the mutant and wild-type Oxa1p. We show
that Oms1p is a mitochondrial inner membrane protein
inserted independently of Oxa1p. Oms1p presents one
TM and a N-in C-out topology with the C-terminal do-
main carrying the methyltransferase-like domain. A
conserved motif within this domain is essential for the
suppression of oxa1 mutations. We discuss the possible
role of Oms1p on Oxa1p intermembrane space domain.
Mitochondria are organelles that are essential for numerous
metabolic reactions, including the oxidative phosphorylations
that provide non-photosynthetic eukaryotic cells with their
major source of ATP. The mitochondrial inner membrane con-
tains the respiratory chain complexes and ATP synthase as
well as numerous other proteins, such as transporters and
translocators. This extremely high protein content makes the
mitochondrial inner membrane a good model system to study
how hydrophobic proteins from different origins can reach their
final destination and acquire their proper topology and their
assembly partners in a lipid bilayer.
Most of the proteins synthesized in the cytoplasm and im-
ported into the mitochondrial membrane are dependent on the
Tom and Tim translocases from the outer and inner mem-
branes (for review see Ref. 1). Other factors are necessary to
ensure the correct insertion of the small number of respiratory
complex subunits that are encoded by the mitochondrial ge-
nome and inserted within the inner membrane. First, at least
in Saccharomyces cerevisiae, specific translational activators
bound to the membrane recognize the 5-untranslated leaders
of most mitochondrial mRNAs and probably contribute to lo-
calize mitochondrial translation in the vicinity of the mem-
brane, facilitating subsequent membrane integration of the
newly synthetized peptides (2). The modulation of mitochon-
drial protein synthesis can also promote its coupling with mem-
brane insertion (3). Second, in eukaryotic mitochondria, Oxa1p
is an important inner membrane component mediating mem-
brane insertion of mitochondrial proteins and the export of
some domains that have to be translocated into the intermem-
brane space. In particular, Oxa1p could be crucial for the in-
sertion and lateral exit of mildly hydrophobic transmembrane
(TM)1 segments (4) and for the translocation of charged soluble
domains (5).
Oxa1p is functionally conserved in higher eukaryotes (6, 7),
and the Oxa1p family extends far beyond eukaryotic mitochon-
dria because members are present in both bacteria, such as
YidC, and chloroplast (8–10). In the yeast S. cerevisiae, the
deletion of the OXA1 gene prevents respiratory growth because
it impairs the biogenesis of the three respiratory complexes of
dual genetic origin, cytochrome c oxidase being the most af-
fected (11, 12). In particular Oxa1p seems essential for the
co-translational insertion of Cox2p, which is encoded by the
mitochondrial genome and the export of its soluble domain
within the intermembrane space (13–16). In Escherichia coli,
YidC interacts with the Sec system to function as a membrane
insertase. In particular, YidC is required for the insertion of
ATPase subunits (9, 17–19). In Arabidopsis chloroplasts, the
Alb3 protein mediates the insertion of the light antenna com-
plexes into the thylakoid membrane (20). The Chlamydomonas
Alb3 is also required for efficient assembly of photosystem II
(21). The Oxa1p, YidC, and Alb3 proteins share modest se-
quence homology but show a conserved structure with five or
six TM segments interrupted with hydrophilic loops located on
either side of the membrane (22, 23). YidC contains six TM
domains, and both its C and N termini are located in the
cytoplasm. In eukaryotes, Oxa1p-type proteins show a N-out
C-in topology (24) and five TM domains with a long basic
C-terminal tail.
In an effort to analyze the domains of Oxa1p and to examine
how its structure relates to its function and the interaction
with its substrates, we have introduced point mutations and
large deletions into various domains of the protein that are
located in the membrane, the intermembrane space, or the
matrix. We find that mutating two TM residues specific to the
eukaryotic members of the family specifically affects cyto-
chrome c oxidase activity. In addition, the two matrix regions of
Oxa1p appear dispensable independently but their simultane-
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ous removal causes a severe respiratory deficiency. These mu-
tants led to the isolation of a high copy suppressor, OMS1,
which encodes a mitochondrial inner membrane protein of the
methyltransferase family. The suppression mechanism has
been investigated, and its functional implications are
discussed.
EXPERIMENTAL PROCEDURES
1. Strains, Media, and Genetic Techniques—All of the strains were
derived from the W303 nuclear backgroundMAT ade2–1 ura3–1 his3–
11,15 trp1–1 leu2–3,112 can1–100. CW04 is the wild-type strain (11),
NBT1 is the oxa1::LEU2 strain (6), and NBT3 is the oxa1::URA3
strain (12). The thermosensitive strain (oxa1-ts1402) (25) in which
leucine 240 of Oxa1p is substituted by serine was constructed by K. Hell
and R. A. Stuart. The mba1 strain was from J. M. Herrmann. The
afg3 strain (afg3::HIS3) was from A. Tzagoloff. Media and genetic
techniques were as described previously (11).
2. Subcloning and Site-directed Mutagenesis—The 3-kb SacI KpnI
fragment containing the OXA1 ORF was subcloned into the same sites
of pRS416, a centromeric plasmid (26), to yield pNB160. Mutant DNA
fragments were obtained by two-step PCR as described previously (27).
In mutant WW3AA, codons 128–129 (TGG TGG) were replaced by
GCA GCT, creating both a PstI and a PvuII site with the flanking
wild-type nucleotide. Codon 140 (CGA) encoding arginine was changed
to GCA (alanine), creating an HpaI site, or to GAA (glutamate). Codons
332 and 353 were changed from AAA (lysine) to the stop codon TAA, and
codon 376 was altered from TTA (leucine) to GTA. Simultaneously, a
NcoI, HpaI, or SpeI site was created downstream stop codon 332, 353,
or 376, respectively. Deletion of the 43 codons of L1 created an HpaI
site. Deletion of L2 or TM4–5 removed 25 and 33 codons, respectively.
Mutant OXA1 fragments were subcloned into pNB160 using various
restriction sites located throughout the OXA1 ORF. All of the plasmids
generated were verified by sequencing the regions coming from PCR
amplification and the cloning junctions. For some mutants, the SacI
KpnI 3-kb fragment was subcloned into the high copy URA3 vector
YEp352 (28).
3. Homologous Recombination—The oxa1mutations were integrated
into the genome. However, as the different C-terminal truncations
showed a similar phenotype on plasmid, only the largest one, K332*,
was chosen for homologous integration into the yeast genome. The
resulting oxa1 mutation was identical to that carried by the oxa11–331
mutant used by Szyrach et al. (16). SacI KpnI linear fragments contain-
ing the mutated OXA1 genes were mixed with a circular LEU2 vector
(Yep351) (28) and used to transform the oxa1::URA3 strain NBT3.
[Leu] transformants were selected and replica-plated onto medium
containing 5-fluoro-orotic acid, which is toxic in [Ura] cells, to screen
for [Leu] [Ura] clones. The phenotype of each recombinant strain was
similar to that of a oxa1 strain expressing the corresponding mutant
gene from a centromeric plasmid. The structure of the OXA1 locus was
confirmed by PCR analysis and sequencing for each strain.
4. Library Screening—Mutant WW3AA was transformed with a
high copy library constructed by F. Lacroute into the URA3 2  vector
pFL44L. [Ura] clones were selected and replica-plated onto glycerol
medium at 36 °C. Total yeast genomic DNA was extracted from three
co-segregating slow-growing [Gly] clones and used to transform E. coli
cells to recover the plasmids. Molecular analysis by restriction enzymes
and sequencing showed that two plasmids were carrying truncations of
OXA1 itself and that the last one, pNB212, contained a new chromo-
some IV insert carrying the YDR316w/OMS1 gene.
5. Mutagenesis of OMS1—A 1.76-kb SacI SphI fragment containing
OMS1 was excised from a deletion derivative of pNB212 (Fig. 3A, line
6) and subcloned into the same sites of vector Yep352 (28). This new
plasmid, pNB229, still carried the suppressor activity and contained
two XbaI sites 554 bp apart surrounding the third methyltransferase
motif coding region of OMS1 (motif II, see Fig. 6A). A PCR primer was
designed that contained the first XbaI site and a modified motif II
coding region. Codon 326, which was coding for aspartate, was changed
from GAT to GCA (alanine). In addition, the following codon was altered
from ACT (threonine) to TCT (serine), which allowed the creation of a
NsiI while still coding a hydroxylated amino acid at position 327.
Previous studies have shown that this position did not matter for the
methyltransferase activity (29). A mutated version of the XbaI 554-bp
fragment was generated by PCR amplification and subcloned in-frame
into the XbaI sites of pNB229 to replace the wild-type fragment. In this
new plasmid, pNB230, the expected mutation was verified by the pres-
ence of the NsiI site followed by sequencing of the cloned XbaI fragment
and junctions.
6. Epitope Tagging and Deletion of OMS1—Oms1p was tagged by
fusing the c-Myc epitope at the last residue (amino acid 471) using PCR
fragments containing 41 and 43 bp homologous to OMS1 on the 5 and
3 sides of the c-myc-HIS3 cassette (30). The PCR fragment was intro-
duced into a wild-type strain, either untransformed or carrying the
pNB212, pNB229, or pNB230 OMS1 plasmids to integrate the c-Myc
construct either in the yeast genome or in the plasmid. Correct inte-
gration of the tag in theOMS1ORF was confirmed both on genomic and
on plasmidic DNA by PCR amplification and sequencing. The genomic
version of OMS1 was deleted using a KanR PCR fragment that contains
50 bp of the OMS1-flanking regions on each side. The integration was
confirmed by PCR analysis of the genomic DNA, and the [G418R]
phenotype was shown to segregate 2:2 and to correlate with the pres-
ence of the disrupted version of OMS1.
7. Mitochondria Purification, Western Blotting, Determination of Res-
piratory Complex Activities, and 35S Labeling—Cells were grown either
in complete or minimal galactose medium, and mitochondria were
purified as described previously (31). Swelling and protease K treat-
ment of mitochondria were carried out as described previously (32).
Mitochondria were analyzed by SDS-PAGE followed by blotting onto a
nitrocellulose membrane and hybridization with various antibodies:
anti-Cox2p and anti-porin (Molecular Probes); anti-cytochrome c1
(raised in our laboratory against a fusion protein ProA-apocytochrome
c1 expressed in E. coli); anti-Atp2p and anti-Atp4p (J. Velours); anti-c-
Myc (J. M. Galan); and anti-Arg8p (T. D. Fox). Immunodetection was
carried out using the standard chemiluminescence method. To measure
the cytochrome c oxidase activity, the oxidation of previously reduced
cytochrome c was followed spectrophotometrically at 550 nm according
to Pajot (33). Ubiquinol cytochrome c oxidase activity (bc1 activity) was
measured according to Brasseur et al. (34). Oligomycin-sensitive
ATPase activity was measured by colorimetric determination of inor-
ganic phosphate released from ATP according to Spannagel et al. (35).
35S labeling of mitochondrial proteins was performed on whole cells in
the presence of cycloheximide that specifically blocks cytoplasmic trans-
lation as described by Lemaire et al. (36).
RESULTS
1. Mutations in Different Domains of Oxa1p Lead to Different
Respiratory Growth Phenotypes—To investigate the function of
the different domains of Oxa1p, mutations were created in the
gene on a centromeric plasmid using a PCR-based site-directed
mutagenesis strategy and then integrated at the chromosomal
OXA1 locus (Fig. 1A). First, missense mutations were intro-
duced in or close to the sequences encoding the first hydropho-
bic segment TM1. The pair of tryptophans 128–129, specific to
eukaryotic Oxa1p/Alb3p-type sequences, was changed to a pair
of alanines (WW3AA), whereas the basic arginine 140 adja-
cent to TM1 was substituted by either the neutral alanine
(R140A) or the acidic glutamate residue (R140E). Second, non-
sense mutations were placed in the 3 end of OXA1 to generate
three different truncations of the C-terminal tail of Oxa1p
(K332*, K353*, and K376*). Third, large deletions were made
within loop 1 (L1) or loop 2 (L2) or by fusing loop 3 to the
C-terminal tail to eliminate TM4 and TM5 (TM4–5).
The phenotypes of these various mutants were analyzed on
respiratory media containing different non-fermentable carbon
sources (ethanol/glycerol/lactate), which cannot sustain growth
of the null mutant oxa1 (Fig. 1B). The missense mutations
WW3AA in TM1 led to a very strict thermosensitive and
slightly cryosensitive phenotype on non-fermentable medium,
whereas modification of Arg140 (R3E, R3A) only conferred a
cryosensitive phenotype on lactate medium. Similar to the
oxa1 mutant, L2 and TM4–5 did not grow at all on these
non-fermentable media. L1 and the truncations of the C-
terminal tail of Oxa1p were indistinguishable from the wild
type at 28 °C, although K332* showed some weak sensitivity to
either high or low temperatures. It was striking that L1 and
K332* gave mild phenotypes while deleting such large matrix
parts of the protein, so we constructed a double mutant L1-
K332* by combining both matrix mutations. This L1-K332*
mutant does not grow on non-fermentable medium.
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2. Effect of the Various Mutations on the Steady-state Level of
Oxa1p and on the Assembly of the Respiratory Complexes—The
mutants were subjected to biochemical analysis to determine
both the steady state-level and size of the Oxa1p variants and
the effect on respiratory complex biogenesis. With the excep-
tion of L2 in which the Oxa1p protein was repeatedly unde-
tectable, the mutated Oxa1p could be detected in purified mi-
tochondrial extracts in all of the other mutants but always in
lower steady-state levels than in the wild type (Fig. 2A). We
could find no correlation between the levels of Oxa1p variants
and either the nature of the mutation or the strength of the
phenotype. Rather Oxa1p levels seemed extremely sensitive to
any type of mutation. This could be due to the fact that Oxa1p
is known to facilitate its own insertion (37) and is very sensitive
to proteases (38). For all of the mutants, the observed size of
the Oxa1p variants was compatible with the predicted size.
Strikingly, the level of the Oxa1p variant observed in WW3AA
was similar whether it was at permissive or restrictive temper-
ature, suggesting that the mutated protein activity rather than
its accumulation is affected by high temperature. In addition,
the level of the L1-K332* was similar to that of the two single
mutants, showing that the large double deletion did not further
destabilize Oxa1p.
In absence of Oxa1p, the N-tail translocation of the Cox2p
precursor into the intermembrane space is blocked (25). Con-
sequently, the maturation of pre-Cox2p cannot occur and the
unprocessed precursor is rapidly degraded. The new mutants
were subjected to 35S labeling of the mitochondrial proteins at
28 °C (Fig. 2B). As usual, in this strain background, the cyto-
chrome b labeling signal was stronger when Oxa1p function
was affected.2 Whereas Cox2p was entirely matured in L1
and K332*, L2 and TM4–5 behaved like oxa1 mutants.
Interestingly, R3A and WW3AA, which showed wild-type
growth on non-fermentable carbon source at 28 °C, were partly
defective in pre-Cox2p processing, similarly to L1-K332*,
which exhibited a strong respiratory-deficient phenotype. This
finding suggests that the respiratory growth deficiency of L1-
K332* was due to respiratory chain biogenesis defect that was
distinct from pre-Cox2p membrane insertion.
The effect of these oxa1 mutations on respiratory complex
assembly was further analyzed by combining immunodetection
experiments and respiratory enzyme activity measurements on
purified mitochondria. First, Western blot analysis of the
steady-state level of three representative subunits of cyto-
chrome c oxidase (Cox2p), complex bc1 (Cyt1p), and ATPase
(Atp4p) was performed for all of the mutants (Fig. 2A). At
28 °C, R3A, L1, K332*, and WW3AA behaved similarly to
the wild type, whereas TM4–5 was similar to the oxa1
mutant. L1-K332* grown at 28 °C and WW3AA grown at a
restrictive temperature showed an intermediate phenotype.
Second, respiratory enzyme activity measurements were per-
formed for the two latter mutants (Table I). L1-K332* exhib-
ited a dramatic 90% decrease in cytochrome c oxidase activity
2 C. Lemaire, unpublished data.
FIG. 1. Oxa1p mutant structures and growth phenotypes. A, a
putative topology of Oxa1p is presented with its five TM segments
within the inner membrane of mitochondria (IM). The N terminus (N)
is in the intermembrane space (IMS) and the C terminus (C) in the
matrix. Each circle corresponds to an amino acid, starting from position
43, as the Oxa1p presequence is expected to be cleaved around this
position (24). Residues altered to non-sense mutations in the C-termi-
nal tail of Oxa1p are depicted in black, whereas missense mutations at
positions 128–129 and 140 are shown in dark gray. Residues deleted
are filled in light gray. The position of the substitutions or the inclusive
limits of the deletions are indicated. Names of the various mutants are
given in boldface letters. B, 10-fold serial cell dilutions of the integrated
mutants were spotted onto complete medium containing various carbon
sources and incubated at different temperatures for 2–22 days depend-
ing on the temperature or the carbon source. Glucose is a fermentable
carbon source, whereas glycerol, ethanol, and lactate are non-
fermentable.
FIG. 2. Biochemical analysis of the mutants. A, mitochondria
were extracted from cells grown at 28 (left panel) or 33 °C (right panel).
Mitochondrial proteins were run on a 12% acrylamide gel before West-
ern blotting with the anti-Oxa1p antibody and with anti-Cox2p, anti-
Cyt1p, and anti-Atp4p antibodies. Stars indicate the band correspond-
ing to the Oxa1p variants in each lane, and the dot shows a nonspecific
signal present even in the oxa1 strain. Molecular masses are given on
the right side. B, cells were grown at 28 °C and labeled with [35S]me-
thionine and [35S]cysteine in the presence of cycloheximide for 20 min.
The newly translated mitochondrial products were separated on a 16%
acrylamide-0.5% bis gel (51) before exposure. The level of processed
Cox2p has been determined for each mutant using the ImageQuant
program (Molecular Dynamics) and is given as an average percentage of
wild type.
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and at least a 50% decrease in bc1 and ATPase activities. At
restrictive temperature, WW3AA presented a specific defect
of cytochrome c oxidase, whereas the ATPase and the bc1
activities were nearly wild type. Thus, all of the biochemical
analyses showed that L1-K332* has a pleiotropic phenotype
that reflects the requirement of the matrix domains for the
biogenesis of the three respiratory complexes, whereas
WW3AA specifically affects cytochrome c oxidase formation at
high temperature.
3. YDR316w/OMS1 Is a High Copy Suppressor of Partial
oxa1 Defects That Genetically Interacts with OXA1—Contrary
to the oxa1 mutant, WW3AA presented spontaneous rever-
sion events of the respiratory deficiency at 36 °C and thus
appeared less stringent than oxa1. This led us to search for
high copy suppressors of WW3AA, even though no high copy
suppressors of oxa1 had ever been isolated. A genomic library
cloned in a high copy vector was introduced into WW3AA
cells, and colonies presenting a slow growth phenotype on
non-fermentable carbon sources were further analyzed. One of
them contained a plasmid carrying a 3.9-kb fragment of chro-
mosome IV that conferred suppression after re-transformation
of both the original mutant WW3AA and the L1-K332* mu-
tant but only at 28 °C for L1-K332* (Fig. 3A and data not
shown). This 3.9-kb fragment contained two entire ORFs,
YDR316w and IPK1/YDR315c, together with the 5 region of
YDR314c. Subcloning and disruption showed that the gene
responsible for the suppression was YDR316w, an ORF of
unknown function, that we called OMS1 for “Oxa1 Multicopy
Suppressor” (Fig. 3A).
In theory, Oms1p could compensate only for all/some oxa1
deficiencies or it could generally improve the non-fermentable
growth efficiency of many conditional respiratory mutants. To
decide between these possibilities, we determined the allele
specificity of the suppression. Several oxa1 mutants were
transformed with the plasmid carrying OMS1 and tested for
growth on glycerol medium at 28 or 36 °C (data not shown).
Whereas oxa1, L2, or TM4–5 clearly was not suppressed,
the mutant oxa1-ts1402 corresponding to a thermosensitive
substitution of leucine to serine (25) was suppressed similarly
to WW3AA and L1-K332* (data not shown). Mitochondria
were purified from the L1-K332* transformants carrying the
OMS1 plasmid, and Western blot analysis revealed that over-
expression of OMS1 slightly increased the steady-state level of
Cox2p (Fig. 3B). To analyze the gene specificity of the suppres-
sion, we also transformed various nuclear or mitochondrial
mutants showing either thermosensitive or leaky respiratory
phenotypes. We found that the mba1 (39), nam1 (40),
cox2–10 (41), and cbs2–223 (42) mutants were not suppressed
(data not shown). Thus, the multicopy suppressor phenotype of
OMS1 is specific to some of the alleles of OXA1.
To study the function of Oms1p, we deleted the gene. The
doubling time of the oms1 cells was slightly longer than that
of the isogenic wild-type cells grown in liquid glycerol medium
(4 h instead of 2 h 30 min for the wild type at 28 °C). No
synergistic growth defect was detected when oms1 was com-
bined with oxa1. However, a strong interaction was observed
in a WW3AA thermosensitive background, since the combina-
tion of the WW3AA and oms1 mutations prevented growth
on non-fermentable medium already at 28 °C (Fig. 3C) and not
only at 36 °C as in the WW3AA single mutant (Fig. 1B). This
growth defect at 28 °C was complemented by the introduction
of the OMS1 plasmid (data not shown). Thus, the absence of
Oms1p appears only mildly deleterious for respiration except
when combined with a specific oxa1 mutation.
TABLE I
Respiratory chain enzyme activity in some oxa1 mutants
Mitochondria were purified from cells grown in complete galactose
medium at the indicated temperature, 28 or 33 °C. However, activities
were all recorded at 28 °C. III, ubiquinol cytochrome c oxidoreductase
activity was in the wild type of 514 or 538 nmol of reduced cytochrome
c/min/mg protein for cells grown at 28 or 33 °C respectively. IV, cyto-
chrome c oxidase activity was in the wild type of 371 or 390 nmol of
oxidized cytochrome c/min/mg protein for cells grown at 28 or 33 °C. V,
ATPase activity was in the wild type of 1.7 or 1.9 mol of ATP hydro-
lyzed/min/mg protein for cells grown at 28 or 33 °C. Mutant activities
are expressed as the percentage of wild-type absolute activities. All of
the values were a mean of 3–5 repeats. Means  S.D. were comprised
of 10 and 20% of the measurements.
Growth temperature Strain
Activities at 28 °C
III IV V
° C
28 WT 100 100 100
WW3AA 104 88 94
 L1-K332* 35 10 50
oxa1 19 0 16
33 WT 100 100 100
WWAA 109 17 84
FIG. 3. Identification and phenotype of a high copy suppressor
of oxa1 mutants. A, L1-K332* cells transformed with the indicated
constructs carried by the vector pFL44L were patched on minimal
glucose medium lacking uracil (Glc) and replica-plated onto a non-
fermentable carbon source (ethanol-glycerol). The plates were incu-
bated for 4 days. The first patch corresponds to cells transformed with
the wild-type OXA1 gene carried by pFL44L, and cells from the second
patch contain the empty vector. The third patch corresponds to plasmid
pNB212 carrying the chromosome IV insert containing the suppressor
gene OMS1. The arrows show the direction of transcription of the
different ORFs. The following patches correspond to deletion deriva-
tives of pNB212. The white KanR box represents the marker gene
conferring resistance to the G418 drug, inserted in the BstEII site at the
very beginning of the OMS1 ORF on plasmid pNB212. The transfor-
mants analyzed in B are marked with a circle. B, mitochondrial proteins
of the indicated transformants from A (vector or expressing high copy of
OXA1 orOMS1) were separated on a 12% gel, blotted, and hybridized to
the anti-Cox2p and anti-Arg8p antibodies. The Cyt1p signal corre-
sponds to the direct detection of heme c chemiluminescence (52). C, a
diploid homozygous for the thermosensitive oxa1 allele encoding
Oxa1p-WW3AA and heterozygous for the deletion of OMS1 was sub-
jected to sporulation, and asci were microdissected. Growth of the
spores was compared on complete glucose medium supplemented (Glc
G418) or not (Glc) with the G418 antibiotic that selects for oms1 and
on non-fermentable glycerol medium (Gly 28 °C). Numbers 1–5 refer to
five different tetrads. Letters A through D indicate the four sister
spores. All of the 30 tetrads obtained showed identical results.
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4. OMS1 Encodes an Integral Inner Mitochondrial Mem-
brane Protein Inserted Independently of Oxa1p with a N-in
C-out Orientation—Oms1p is a 471-residue protein that con-
tains two domains separated by a predicted TM helix starting
around residue 108. The large C-terminal domain shows ho-
mologies with a large number of eukaryotic and prokaryotic
proteins from the methyltransferase family (43). The shorter
N-terminal domain presents a possible mitochondrial targeting
presequence followed by a region devoid of homology to any
protein of known function in the data base. Strong homologs of
Oms1p that also exhibit a predicted TM segment upstream of
their methyltransferase-type domain appear to be present only
in other fungi (data not shown).
To determine whether Oms1p was located in the mitochon-
dria, we generated a strain where the genomic wild-type OMS1
gene was fused just before the stop codon to the c-Myc epitope.
As a control, this tagged derivative was cloned on a high copy
plasmid and this construction was still able to suppress the
growth defect of the L1-K332* (Fig. 4A). Purified mitochon-
dria from the tagged Oms1p-c-Myc strain as well as the post-
mitochondrial supernatant were probed with antibodies recog-
nizing the c-Myc epitope, the cytosolic phosphoglycerate
kinase, or the mitochondrial protein Atp2p (Fig. 4B). Atp2p and
c-Myc signals were recovered only in the mitochondrial fraction
(lane 1), whereas phosphoglycerate kinase was found only in
the post-mitochondrial supernatant (lane 2), showing that
Oms1p-c-Myc is targeted to mitochondria.
Oms1p is predicted to span the membrane once. To test
whether Oms1p-c-Myc was associated or not with mitochon-
drial membranes, we “alkali”-treated purified mitochondria
from tagged cells to extract all of the non-integral membrane
proteins. As shown in Fig. 4B (lanes 3 and 4), Oms1p-c-Myc is
found in the pellet fraction, similarly to the outer membrane
porin and contrary to the matrix protein Arg8p. Thus, Oms1p
is an integral mitochondrial membrane protein. The addition of
proteinase K to intact mitochondria did not degrade the
Oms1p-c-Myc protein or modify its mobility, showing that
Oms1p does not span the outer membrane but instead is lo-
cated in the inner membrane (Fig. 4C, lane 2). To determine the
topology of Oms1p, osmotic swelling was performed on Oms1p-
c-Myc mitochondria in the presence of protease to digest all of
the outer membrane and intermembrane space proteins. De-
pending on the concentration of proteinase K used, the protease
treatment partially or completely eliminated the c-Myc epitope
attached to the C terminus of Oms1p (Fig. 4C, lanes 3 and 4),
whereas the matrix protein Arg8p remained protected, show-
ing that Oms1p C terminus is located in the intermembrane
space.
Because Oxa1p is involved in the membrane insertion of
various mitochondrial proteins, it could be required for the
proper anchoring of Oms1p into the membrane. This would
explain why the over production of Oms1p cannot compensate
for the complete absence of Oxa1p. To determine whether
Oms1p was still associated with the membrane fraction in the
absence of Oxa1p, we isolated mitochondria from a tagged
Oms1p-c-Myc strain lacking Oxa1p. We found that similar
amounts of Oms1p-c-Myc accumulated in the mitochondria and
remained associated with the pellet upon alkali treatment (Fig.
4B, lanes 5 and 6) in the presence or absence of Oxa1p. This
showed that proper insertion of Oms1p-c-Myc is independent of
Oxa1p function.
5. OMS1 Overexpression Appears to Increase the Steady-state
Level of Both the Mutant and Wild-type Oxa1p—Reciprocally,
Oms1p could be required to stabilize mutant and/or wild-type
Oxa1p. To test this hypothesis, we extracted mitochondrial
proteins from a wild type and a oxa1 strain as well as from
L1-K332* cells transformed with a control vector (lane 5), a
plasmid overproducing Oms1p-c-Myc (lane 4) or Oxa1p (lane 3).
The level of the wild-type and mutant Oxa1p was analyzed in
the extracts (Fig. 5A). First, the levels of both the wild-type
Oxa1p and the Oxa1p-L1-K332* were increased by 3-fold
compared with Arg8p levels when the wild-type Oxa1p was
overproduced (lane 3 compared with lanes 1 and 5). Second, the
mutant L1-K332* protein level was also 4-fold higher com-
pared with Arg8p levels when OMS1 was overexpressed (lane 4
compared with lane 5), showing that an overexpression of
OMS1, similar to the overexpression of the wild-type OXA1
gene, can increase the steady-state level of the mutant Oxa1p.
It was tempting to hypothesize that this increase in the
L1-K332* steady-state level by Oms1p could account for the
suppression. In this case, direct overexpression of the mutated
oxa1 genes from a high copy plasmid would be predicted to
compensate for the deletion of OXA1. We found that the L1-
K332* and WW3AA mutants could compensate for OXA1
FIG. 4. Mitochondrial sublocalization and topology of Oms1p.
A, L1-K332* cells were transformed with the empty vector pFL44L,
the OMS1 plasmid pNB212, or its c-Myc tag derivative. Transformants
were patched on glucose minimal medium before replica-plating onto
non-fermentable medium containing ethanol and glycerol and incu-
bated for 4 days at 28 °C. B, left panel, mitochondrial (lane 1) and
cytosolic (lane 2) protein fractions of a Oms1p-c-Myc-tagged strain were
separated and blotted with anti-c-Myc antibody as well as control an-
tibodies recognizing known cytosolic phosphoglycerate kinase (PGK) or
mitochondrial (Atp2p) markers. Right panel, mitochondrial proteins
from Osm1p-c-Myc cells containing either the wild type Oxa1p (OXA1,
lanes 3 and 4) or devoid of Oxa1p (oxa1, lanes 5 and 6) were purified
and alkali-treated to separate the soluble proteins recovered in the
supernatant (S) from the integral membrane proteins that stayed in the
pellet (P). The different samples were analyzed by Western blotting
using the anti-c-Myc antibody and control antibodies specific either to a
soluble mitochondrial matrix protein (Arg8p) or an integral mitochon-
drial membrane protein (Porin). C, mitochondrial proteins (lane 1)
extracted from Oms1p-c-Myc cells were treated with proteinase K (PK)
before (lane 2) or after (lanes 3 and 4) swelling to rupture the outer
membrane while keeping the inner membrane intact. The three differ-
ent extracts were blotted with the anti-c-Myc antibody or a control
antibody recognizing the matrix protein Arg8p.
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deletion when expressed from a high copy vector, even at 36 °C
(Fig. 5B).
In a similar way, the overexpression of OMS1 could act on
the wild-type Oxa1p. It is known that overexpression of OXA1
suppresses the respiratory defect due to the absence of Afg3p,
a protease facing the matrix side of mitochondria (44, 45).
Thus, we transformed the OMS1 plasmid in the afg3 mutant
and observed that the afg3 respiratory deficiency is clearly
compensated by overexpression ofOMS1 (Fig. 5B). This finding
suggests that the suppression of afg3 mediated by high copy
of OMS1 occurs through stabilization of the wild-type Oxa1p.
Overproduction of the Oxa1p variants WW3AA or L1-K332*
or of the CYT1-1 suppressor of the OXA1 deletion (46) could not
overcome the respiratory deficiency of afg3 cells. Taken to-
gether, our results indicate that overproduction of Oms1p af-
fects the accumulation of both wild-type and mutant Oxa1p.
6. A Point Mutation in a Conserved Methyltransferase Motif
Abolishes the Suppression of oxa1 Mutations—Oms1p belongs
to the family of yeast methyltransferases based on its good
match with the four typical motifs conserved in a large number
of these enzymes (Fig. 6A) (43). Thus, it was of interest to
determine whether the methyltransferase activity of Oms1p
was involved in the suppression. However, to be conclusive, a
mutagenic analysis should not lower Oms1p steady-state level
because Oms1p-mediated suppression functions only as high
dosage.
In rat guanidinoacetate methyltransferase, a widely con-
served aspartate residue in the third conserved motif (motif
II) has been shown to be crucial for the activity of the enzyme.
Mutation into glutamate substantially lowered the activity,
whereas mutation into alanine led to inactivation (29). In
addition, neither the secondary and tertiary structures of the
enzyme nor its stability were affected. It was also shown that
conservative change of the residues flanking the aspartate
did not affect either the activity or stability of the enzyme
(29).
We introduced by PCR-mediated mutagenesis a mutation in
Oms1p motif II (Fig. 6A). The aspartate was changed to ala-
nine, and for convenience, the threonine adjacent to the aspar-
tate was changed to serine, i.e. a conservative change. The
mutant gene was cloned on a high copy plasmid and trans-
formed into the L1-K332* mutant together with the wild-type
control plasmid. Whereas the suppression was clearly seen in 4
days with wild-type plasmid, the mutant plasmid was unable to
suppress like the empty vector (Fig. 6B).
To make sure that the mutant protein was indeed expressed
and stable, we tagged with the c-Myc epitope sequence both the
FIG. 5. Interaction between Oms1p and Oxa1p. A, L1-K332*
mutant cells were transformed with plasmids overproducing Oms1p or
Oxa1p or with the empty control vector. Mitochondria were purified
from the transformants and from wild-type and oxa1 controls, and
mitochondrial proteins were analyzed by Western blotting using the
anti-Oxa1p, anti-Atp4p, and anti-Arg8p antibodies. The two upper pan-
els correspond to different exposures and different regions of the same
membrane obtained from the hybridization experiment with the anti-
Oxa1p antibody. Band density values were measured using the Image-
Quant program. B, the wild type, WW3AA, or L1-K332* versions of
the OXA1 gene were cloned on a high copy vector. The resulting plas-
mids as well as plasmids overexpressing OMS1 or the CYT1-1 domi-
nant suppressor known to compensate for oxa1 mutants (46) were
transformed in the oxa1 and in the afg3 mutant together with a
control vector. Growth of the transformants on glycerol medium was
analyzed at 28 and 36 °C. Glycerol plates were incubated for 5 (oxa1
mutants) or 9 days (afg3 mutants).
FIG. 6. Involvement of Oms1p methyltransferase domain in
the suppression of oxa1-L1-K332*. A, Oms1p is depicted with its
four conserved methyltransferase motifs, I, post-I, II, and III (white
bars). The sequence of the motifs is given in the one-letter code, and
the numbers refer to the number of residues in between the motifs.
Residues or spaces are boxed in gray when they fulfill the consensus
found by Niewmierzycka and Clarke (43). In the Oms1p-AS variant,
the widely conserved Asp326 and the loosely conserved Thr237 have
been modified to Ala and Ser respectively. B, high copy plasmids
producing the wild-type Oms1p or the mutant version Oms1p-AS as
well as the control vector Yep352 have been transformed into the
L1-K332* mutant. Transformants were patched on selective glucose
medium (Glc), replica-plated onto non-fermentable plates (Eth/Gly),
and incubated at 28 °C for 4 days. C, the L1-K332* mutant was
transformed with plasmids overexpressing either the untagged
OMS1 gene or c-Myc-tagged versions of the wild type (OMS1-c-Myc)
or mutant gene (OMS1-AS-c-Myc). Purified mitochondrial proteins
were analyzed by Western blotting using an anti-c-Myc or anti-Atp2p
antibody.
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wild-type and mutant OMS1 genes carried on the high copy
plasmid and measured the accumulation of the tagged protein
in purified mitochondria. Western blot analysis showed that
the mutation in Oms1p motif II did not modify its stability (Fig.
6C), thus demonstrating that the loss of the suppression was
indeed due to the mutation itself and not to a lower dosage
of Oms1p.
Together these results show that Oms1p methyltransferase-
conserved motif II is essential for the suppression of oxa1
mutations and strongly suggest that Oms1p is indeed a meth-
yltransferase and that this enzymatic activity is responsible of
the suppression.
DISCUSSION
The absence of Oxa1p leads to a highly pleiotropic pheno-
type with defects in the biogenesis of all of the respiratory
complexes that contain mitochondrially encoded subunits,
suggesting that Oxa1p is acting on various substrates and/or
fulfills different functions. In this study, we have created
point or deletion mutants in various domains of the S. cer-
evisiae Oxa1p and determined whether different roles could
be assigned to the different domains. Looking at the pre-
dicted topology of Oxa1p, three main regions were present: 1)
the acidic intermembrane space domain with the N-terminal
end and loop L2; 2) the basic matrix domain containing the
loop L1 and the C-terminal tail; and 3) the TM domains with
the five hydrophobic helices.
Concerning the TM domains, TM4 and TM5 appear essential
and the mutation WW3AA in or close to the TM1 domain
(according to topology predictions) exhibits a stringent thermo-
sensitive respiratory deficiency. Interestingly, this WW3AA
mutant only affects cytochrome c oxidase. The positive charge
Arg140 conserved in the various Oxa1p homologs and located
either within or in the vicinity of TM1 as highlighted by Kuhn
et al. (9) does not appear to be important for function. Concern-
ing the hydrophilic domains, we have shown that L2 is essen-
tial for Oxa1p function, whereas truncations of either L1 or the
C-terminal tail, which both protrude into the matrix, have no
or limited consequences on respiration. However, we observed
a synergistic defect when we combined the deletions of these
two matrix domains. Indeed, in this double mutant L1-K332*,
Oxa1p, although shortened by one-third, still accumulates at
the same level compared with both single mutants but the
assembly of the three last respiratory complexes is now
strongly affected. However, there is a substantial processing of
pre-Cox2p, showing that the remaining parts of Oxa1p are still
relatively efficient in mediating the insertion of pre-Cox2p N
terminus into the membrane. Thus, another process must be
deficient in L1-K332* to explain the respiratory deficiency.
Two recent papers (15, 16) have implicated the C-terminal tail
of Oxa1p in contacting the translating ribosome, thereby me-
diating a co-translational insertion of the newly synthesized
mitochondrial peptides. However the C-terminal tail trunca-
tions show a rather mild phenotype compared with the pheno-
type of the L1-K332* strain. Szyrach et al. (16) have found
that, despite this strong growth on glycerol, the oxa11–331 mu-
tant cannot bind ribosomes in vitro anymore. These results
could simply illustrate the difference between in vivo and in
vitro, i.e. growth could still be obtained in vivo despite a low or
compromised ribosome binding that becomes undetectable in
vitro. In this case, the remaining in vivo ribosome binding
activity of Oxa1p could be due to (i) the production of undetect-
ably low levels of wild-type Oxa1p by readthrough from the
oxa11–331/K332* mutant, (ii) the binding through the remain-
ing 15 residues of the C-tail in the oxa11–331/K332* mutant, or
(iii) cooperative action for ribosome binding through the L1
loop. Indeed the L1 loop of Oxa1p, like the C-terminal tail,
displayed a positively charged coiled-coil structure (16) and
could cooperate with the C-terminal tail in contacting ribo-
somes or translated RNAs to increase the efficiency of the
insertion process.
In E. coli, the gene encoding the YidC homolog of Oxa1p has
been mutated to study the role of the different domains and the
authors concluded that none of the hydrophilic periplasmic or
cytoplasmic domain residues was important for YidC activity
(47). The present study as well as previous work (15, 16, 25)
stressed the role of the intermembrane space loop and the
matrix domains of Oxa1p for function. This difference between
the bacterial and yeast proteins might be explained by the fact
that YidC cooperates with the Sec system (48), whereas the
Sec-type proteins are absent in yeast mitochondria (49). YidC
would function merely as a hydrophobic platform receiving
substrates from the Sec complex to mediate their lateral exit
into the membrane while the mitochondrial Oxa1p, which
exists as a homotetramer (50), would also play at least some
of the various roles of the different proteins of the Sec
complex.
The oxa1 mutants have allowed the identification of a sup-
pressor gene,OMS1, encoding a newmitochondrial inner mem-
brane protein. The overexpression of OMS1 suppresses muta-
tions affecting various domains of Oxa1p: the loop L2 in the
ts1402 mutant; the matrix regions in L1-K332*; and the TM1
segment in WW3AA. So far, nuclear-encoded suppressors able
to compensate for the absence of Oxa1p have been isolated in
two genes, CYT1 and QCR9. Both encode integral membrane
subunits of the bc1 complex. In most cases, the suppressor
mutation created a positive charge in the TM domain of these
proteins (4, 46) For Cyt1-1p, the suppression is clearly driven
by the short N-terminal part containing the mutated TM. It
was proposed that this positively charged TM domain could
compensate for the absence of Oxa1p by being co-inserted with
negatively charged TM segments that are substrates of Oxa1p,
similar to the first TM domain of Cox2p (4). Interestingly, the
hydrophobic stretch of Oms1p was flanked by numerous pos-
itive charges, which were predicted to be part of the TM
segment, and could represent a natural equivalent of the
Cyt1-1p suppressor. Three lines of evidence suggest that this
was not the case. First, when we attached the c-Myc epitope
to the middle of the OMS1 ORF to produce a truncated
Oms1p-c-Myc containing the TM segment but lacking the
methyltransferase domain, the strong suppression of the
oxa1 mutants was lost (data not shown). However, we were
not able to detect the tagged truncated protein, preventing
any definite conclusion to be drawn. Second, we found that
Oms1p overproduction cannot compensate for the complete
absence of Oxa1p, whereas Cyt1-1p does. Third and most
importantly, we found that the mutation of a conserved meth-
yltransferase motif located 200 residues downstream the
TM segment abolishes the suppression. Thus, the two sup-
pression mechanisms clearly differ. The enzymatic activity
and not the TM segment appeared to be responsible for the
suppression by Oms1p.
In addition, similar to OXA1 (44) and contrary to CYT1-1,
OMS1 overexpression is able to compensate for the absence of
the matrix protease Afg3p. This suppression can be linked to
the observation that overexpression of OMS1, similar to the
overexpression of the wild-typeOXA1 gene, increases 4-fold the
steady-state level of the truncated L1-K332* Oxa1p. One
possibility would be that OMS1 overexpression can stabilize
not only the truncated but also the wild-type Oxa1p and thus
mimics an elevated copy number of OXA1, thereby mediating
afg3 suppression. Similarly, the increase in the steady-state
level of the truncated Oxa1p when OMS1 is overexpressed
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seems sufficient to explain the improved growth of the L1-
K332* mutant because overproduction of the truncated L1-
K332* protein can compensate for the complete absence
of Oxa1p.
Whereas the increase of wild-type or mutant Oxa1p could
account for the observed suppressions, the question remains of
how these increases in steady-state levels are mediated. We
observed that overexpression of wild-type OXA1 stabilizes the
mutant L1-K332* protein. Because Oxa1p is known to facili-
tate its own insertion (37) and to exist as homotetramers (50),
a reasonable hypothesis is that the wild-type Oxa1p could form
a complex with the L1-K332* variant and stabilize it and/or
promote its membrane insertion. In the case of OMS1 overex-
pression, a post-translational modification of Oxa1p by Oms1p
could either increase its resistance to proteases like Oma1p
(38) or freeze Oxa1p conformation after membrane insertion to
enhance its stability and optimize its functioning. The methyl-
transferase active site of Oms1p is located in the intermem-
brane space, and Oms1p isoelectric point is highly basic, sim-
ilar to that of the numerous methyltransferases that modify
acidic substrates such as nucleic acids or phospholipids (data
not shown). These observations suggest that the Oms1p sub-
strate should be acidic and located on the external face of the
inner membrane. An obvious possibility is that Oms1p methy-
lates residues of the overall highly negatively charged N-tail or
Loop 2 of Oxa1p, both of which protrude into the intermem-
brane space (Fig. 7). Basic residues are known to be particu-
larly reactive substrates of protein methyltransferases. A sin-
gle arginine is present in Oxa1p intermembrane space domains
at position 221 close to TM2 and could be a potential target of
Oms1p, but it might also be important for the initial steps of
Oxa1p membrane insertion. Alternatively, Oms1p could meth-
ylate phospholipids on the external face of the mitochondrial
inner membrane (Fig. 7). Indeed, some of the bacterial proteins
showing a close similarity to the C-terminal domain of Oms1p
encoded quinone or phospholipid methyltransferases. The mod-
ification of mitochondrial membrane lipid substrates by Oms1p
could modify membrane fluidity and increase the stability of
Oxa1p or its mutant derivatives and/or insertion efficiency of
TM domains. Whether Oms1p acts on Oxa1p or on lipids, both
hypotheses are consistent with the observation that the ab-
sence of Oms1p had only a mild effect on mitochondrial phys-
iology but started to be deleterious when mitochondrial mem-
brane insertion was partly defective such as in the WW3AA
mutant. In addition to enlightening the mechanism of suppres-
sion, the identification of the Oms1p substrate(s) and interact-
ing component(s), e.g. through a synthetic lethal screen on
glycerol medium, will bring new information on its role in
mitochondrial biogenesis or maintenance.
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